Bernstein cuts Regeneron stock price target to $1,000, keeps Outperform
Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.
Goldman Sachs AM Seeks Up to $3 Billion for Climate Credit Fund
Alternative lending giant Goldman Sachs Asset Management is looking to raise as much as $3 billion for a new climate credit ...
Equinix, Inc. (EQIX) Reports 7% Revenue Growth in Q3, Expands AI Infrastructure Partnerships with NVIDIA and Dell
Peter Oppenheimer, the chief of global equity strategy and the head of macro research for Goldman Sachs in Europe, opined ...